Optometrists in Wantagh, NY Accepting Medicare

7 Optometrists found. Showing 1 - 7

Edward Frank Rubin, OD Optometrist Medicare: Medicare Enrolled Practice Location: 3016 Beltagh Ave, Wantagh, NY 11793 Phone: 516-826-3813    Fax: 516-826-3813

Optyx Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1229 Wantagh Ave, Wantagh, NY 11793 Phone: 516-221-2220    Fax: 516-221-2228

Shari Nancy Cohen, OD Optometrist - Corneal and Contact Management Medicare: Medicare Enrolled Practice Location: 1229 Wantagh Ave, Wantagh, NY 11793 Phone: 516-221-2220

Dr. Jennifer Veronica Thomas, OD Optometrist - Corneal and Contact Management Medicare: Medicare Enrolled Practice Location: 2266 Arby Ct, Wantagh, NY 11793 Phone: 516-308-3045

Optometry Associates Of Wantagh, Pc Optometrist Medicare: Medicare Enrolled Practice Location: 3448 Jerusalem Ave, Wantagh, NY 11793 Phone: 516-781-2822

Neil Rubin Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3448 Jerusalem Ave, Wantagh, NY 11793 Phone: 516-781-2822    Fax: 516-783-5764

Br-eyes Ltd Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1174a Wantagh Ave, Wantagh, NY 11793 Phone: 516-221-2220    Fax: 516-221-2228

News Archive

Hospital outpatient ER visits by Medicaid recipients increased more than 6%

SDI, a leading healthcare market insight and analytics firm, today reported that the number of Medicaid-subsidized inpatient hospital stays originating in the emergency room increased more than 6% in 2009 compared to 2008. The growth rate of all inpatient hospital stays that began in the hospital outpatient ER was less at just over 1%.

Alabama experts develop living document that includes new therapies for Hepatitis C virus

When treatment guidelines for a particular disease emerge, they are often published in a peer-reviewed medical journal, which can take up to three years. One University of Alabama at Birmingham infectious diseases expert recently helped develop new Hepatitis C virus (HCV) guidelines that can be updated and published as new data emerge and new therapies are approved.

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

U.S. envoy for N. Korea says administrative concerns over food aid resolved, would not provide details, AP reports

Robert King, the U.S. special envoy for North Korean human rights issues, on Thursday said talks with North Korean officials over food aid had "resolved the administrative issues we were concerned with," although "he declined to disclose details before reporting back to Washington," the Associated Press reports.

Meda's 2010 group sales decrease to SEK 11,571 million

"The Meda Group expects to achieve sales of about SEK 11,400 million and an EBITDA of about SEK 4,400 million."

Read more Medical News

› Verified 6 days ago